Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quizartinib - Daiichi Sankyo Company

Next Previous
Drug Profile

Quizartinib - Daiichi Sankyo Company

Alternative Names: AC-010220; AC-220; ASP-2689; VANFLYTA

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University Hospital Heidelberg; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Solid tumours

Most Recent Events

  • 11 Dec 2023 Efficacy data from the phase-III QuANTUM-First trial in Acute Myeloid Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition Session (ASH-Hem-2023)
  • 09 Dec 2023 Efficacy data from a phase III QuANTUM-First trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 09 Dec 2023 Updated adverse events data from the phase III QuANTUM-First trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top